66045-86-1

Usage

Derivative of naphthalene

This means that the compound is derived from naphthalene, a two-ring aromatic hydrocarbon, by making modifications to the structure.

Contains a nitro group and a benzylidene substituent

These are functional groups present in the molecule, which give it specific chemical properties and reactivity.

Potential applications in organic synthesis, medicinal chemistry, and material science

This indicates the possible uses of the compound in various fields.

Industrial uses as a precursor in the synthesis of other chemicals or as a component in the production of pharmaceuticals

This suggests that the compound may be useful as a starting material or intermediate in the production of other chemicals or drugs.

Handle and store with care due to flammability or reactivity with other chemicals

This is a safety precaution to be taken when working with the compound, as it may be hazardous under certain conditions.

Upstream product

• 99-61-6 3-nitro-benzaldehyde 
• 529-34-0 3,4-dihydronaphthalene-1(2H)-one 
• 68432-16-6 1(2H)-naphthalenone 
• 121-89-1 3-Nitroacetophenone 

Downstream Products

• 151885-83-5 LY₂₇₀₈₁₃ 
• 335206-60-5 4-(3-nitrophenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazolin-2-thione 
• 129116-64-9 4-(m-nitrophenyl)-2-imino-5,6-dihydro-4H-naphtho<1,2-d><3,1>thiazine hydrochloride 
• 66045-96-3 (2RS,3'SR)-3'-(3-nitro-phenyl)-3,4-dihydro-spiro[naphthalen-2,2'-oxiran]-1-one 

Relevant academic research and scientific papers

Ash of pomegranate peels (APP): A bio-waste heterogeneous catalyst for sustainable synthesis of α,α′-bis(substituted benzylidine)cycloalkanones and 2-arylidene-1-tetralones

Abstract: α,α′-bis(substituted benzylidene)cycloalkanones were efficiently prepared from variously substituted aldehydes and cycloalkanones in water by using ash of pomegranate peels (APP) as a catalyst. The APP-catalyst was obtained from bio-waste by simple thermal treatment to dry peels of pomegranate fruit and formation of its active phase was confirmed by FT-IR, XRD, XRF, EDX, SEM, DSC-TGA and BET techniques. The analysis revealed that the present catalyst has basic sites which promote the synthesis of desired products. The main attractions of our protocol are utilization of highly abundant bio-waste-derived catalyst and good-to-excellent yield in shortest reaction time. This green protocol was further extended for structurally diverse 2-arylidene-1-tetralones by condensation of equimolar quantity of aromatic aldehydes and 1-tetralone at low temperature. The catalyst could be quantitatively recovered and reused effectively for five times. Graphic abstract: [Figure not available: see fulltext.].

Evaluation of silica-H2SO4 as an efficient heterogeneous catalyst for the synthesis of chalcones

We report an efficient silica-H2SO4 mediated synthesis of a variety of chalcones that afforded the targeted compounds in very good yield compared to base catalyzed solvent free conditions as well as acid or base catalyzed refluxing conditions.

An efficient synthesis of bio-active fluorescent benzylidine tetralones

Benzylidine tetralones have been synthesized in excellent yields in PEG 600 at room temperature and short time periods. The synthesized compounds are found to have antibacterial activity towards both gram-positive and gram-negative bacteria. The N, N-dialkyl substituted benzylidine tetralones are found to possess fluorescent properties.

Design, synthesis, and interaction study of quinazoline-2(1 H)-thione derivatives as novel potential Bcl-xL inhibitors

Development of inhibitors to antagonize the activities of antiapoptotic Bcl-2 family proteins is of particular interest in cancer chemotherapy. We discovered a quinazoline-2(1H)-thione derivative (DCBL55) as a new Bcl-x L, Bcl-2, and Mcl-1 inhi

Pharmaceutical compounds

The invention provides pharmaceutical compounds of the formula: STR1 in which A - - - B is CH2 --CH2 or CH=CH; X is a pyridine or benzene ring; when X is pyridine n is 0; when X is benzene n is 0, 1 or 2 and when A - - - B is CH

Therapy for diabetic complications

This invention provides a method of treating diabetic complications in mammals which comprises the administration of a compound of the Formula I: STR1 in which n, R1, R2, R3, and R4 are variables.

Methods of using dihydropyrans

Methods of treating an immune disease, cell proliferation, restenosis and vascular smooth muscle cells using the pharmaceutical compounds of the formula STR1 in which R2 is phenyl, naphthyl or heteroaryl selected from thienyl, pyridyl, benzothi